NATCOPHARM logo

NATCO Pharma Limited Stock Price

NSEI:NATCOPHARM Community·₹147.3b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 96 Fair Values set on narratives written by author

NATCOPHARM Share Price Performance

₹822.55
-531.40 (-39.25%)
41.9% undervalued intrinsic discount
₹1,414.71
Fair Value
₹822.55
-531.40 (-39.25%)
44.4% undervalued intrinsic discount
₹1,480.00
Fair Value
Price ₹822.55
AnalystHighTarget ₹1,480.00
AnalystConsensusTarget ₹997.91
AnalystLowTarget ₹710.00

NATCOPHARM Community Narratives

AnalystHighTarget·Updated
Fair Value ₹1.41k 41.9% undervalued intrinsic discount

Global Healthcare Trends Will Expand Affordable Generics Amid Risks

1users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AnalystConsensusTarget·Updated
Fair Value ₹982.64 16.3% undervalued intrinsic discount

High-value R&D And South Africa Entry Will Shape Uncertain Outcomes

2users have liked this narrative
0users have commented on this narrative
52users have followed this narrative
AnalystLowTarget·Updated
Fair Value ₹712 15.5% overvalued intrinsic discount

Falling Revenues And Risky Diversifications Will Weaken Future Outlook

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative

Recent NATCOPHARM News & Updates

Investors Don't See Light At End Of NATCO Pharma Limited's (NSE:NATCOPHARM) Tunnel

Sep 11
Investors Don't See Light At End Of NATCO Pharma Limited's (NSE:NATCOPHARM) Tunnel

Analysts Just Slashed Their NATCO Pharma Limited (NSE:NATCOPHARM) EPS Numbers

Jun 02
Analysts Just Slashed Their NATCO Pharma Limited (NSE:NATCOPHARM) EPS Numbers

There's No Escaping NATCO Pharma Limited's (NSE:NATCOPHARM) Muted Earnings

May 22
There's No Escaping NATCO Pharma Limited's (NSE:NATCOPHARM) Muted Earnings

NATCO Pharma Limited Key Details

₹44.0b

Revenue

₹7.4b

Cost of Revenue

₹36.5b

Gross Profit

₹19.6b

Other Expenses

₹17.0b

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
94.78
Gross Margin
83.11%
Net Profit Margin
38.62%
Debt/Equity Ratio
3.7%

NATCO Pharma Limited Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Flawless balance sheet with proven track record and pays a dividend.

2 Risks
3 Rewards

About NATCOPHARM

Founded
1981
Employees
4199
CEO
Rajeev Nannapaneni
WebsiteView website
www.natcopharma.co.in

NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

Indian Market Performance

  • 7 Days: 1.5%
  • 3 Months: -1.7%
  • 1 Year: -4.7%
  • Year to Date: 0.7%
Over the last 7 days, the market has risen 1.5%, driven by gains of 2.3% in the Financials sector. Longer term the market is actually down 4.7% over the past year. Looking forward, earnings are forecast to grow by 16% annually. Market details ›